

PHARMA IMAGING GROUP

MEETING SUMMARY

MEETING SUBJECT:	Pharma Imaging Group 2013 Telecon
DATE / TIME:	22FEB13 / 11:00 AM EST
PREPARED BY:	Barbara Chandler, Annette Schmid
LOCATION:	Teleconference

DISCUSSION POINTS:

1	<p>Welcome</p> <ul style="list-style-type: none"> • Annette Schmid, PhD from Perceptive Informatics, Inc. and Susanta Sarkar, PhD from Sanofi are the new co-chairs. • Feel free to reach out to colleagues who want to join. • Thanks to Jim Conklin and David Mozley for all their hard work over the past year. • Meeting minutes are posted in the QIBA Wiki http://qibawiki.rsna.org/index.php?title=Extended_Pharma_Imaging_Group
2	<p>Review of PIG Mission Statement</p> <ul style="list-style-type: none"> • PIG representing interests of commercial entities engaged in clinical trials, such as pharma, biotechnology and support industries and other interested parties. • FDA not regarded as a stakeholder in the narrow sense. • PIG to provide an industry driven voice to affect change. • Main interest in higher level and strategic recommendations but may decide to dive into specific details of implementations • Not to overlap with effort of other groups such as QIBA • Brief discussion on potential funding needs - to be explored whether PHARMA group may be interested in supporting the PIG initiative (again)
3	<p>Meeting Schedule</p> <ul style="list-style-type: none"> • Meetings will take place the last Friday of the month (no meeting in Nov. and Dec.) 2013. • One face to face meeting may be scheduled.
4	<p>Name change</p> <ul style="list-style-type: none"> • Should the name Extended Pharma Imaging Group (PIG) be changed? • Potential suggestions: <ul style="list-style-type: none"> ○ <u>I</u>maging <u>N</u>etwork for <u>T</u>herapeutics and <u>D</u>iagnostics <u>D</u>evelopment: INTADD, or ○ <u>I</u>maging <u>N</u>etwork for <u>T</u>herapeutics and <u>D</u>iagnostics: INTAD • Vote will be taken at March meeting.
5	<p>ODAC Audit Methodology</p> <ul style="list-style-type: none"> • Brief summary of July 2012 ODAC meeting • Proposal of DIA/FDA meeting on audit methodology <ul style="list-style-type: none"> ○ DIA needs to hear from a sufficient number of Pharma who will

	<p>participate, PIG to channel the information on voiced interest</p> <ul style="list-style-type: none">• Further discussion of the methods at meeting at end of March• More on the audit methodology is due to be presented at the Society of Clinical Trials Annual Meeting in Boston, 19-22MAY2013• FDA imaging guidance is due, no further news currently available
6	Next meeting 29MAR2013, 11:00 AM EST